Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PARG | Q86W56 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221044 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP3A4SMN1; SMN2GAAMEN1 | |
| SCHEMBL4807789 | 0.79 | GRM2 (0.44) | GRM2ALDH1A1CYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL5414578 | 0.79 | ALDH1A1 (0.60) | GRM2ALDH1A1CYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL219049 | 0.78 | ALDH1A1 (0.43) | ALDH1A1CYP3A4SMN1; SMN2HSD17B10GAA | |
| SCHEMBL3827955 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP3A4GAAMEN1KMT2A | |
| SCHEMBL1653731 | 0.75 | ALDH1A1 (0.65) | ALDH1A1CYP3A4SMN1; SMN2HSD17B10GAA | |
| SCHEMBL11182921 | 0.74 | GAA (0.62) | ALDH1A1CYP3A4SMN1; SMN2GAAPARG | |
| SCHEMBL4803221 | 0.72 | ALDH1A1 (0.43) | ALDH1A1CYP3A4SMN1; SMN2PARGMEN1 | |
| SCHEMBL19485375 | 0.72 | CYP3A4 (0.53) | ALDH1A1CYP3A4SMN1; SMN2PARGMEN1 | |
| SCHEMBL219172 | 0.72 | ALDH1A1 (0.44) | ALDH1A1CYP3A4SMN1; SMN2HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| EP-1412362-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008422-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | GRM2 2924/4885ALDH1A1 401/4885CYP3A4 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.